News Briefing channel feed

Two fast track des­ig­na­tions for Corey Good­man's new start­up; Vi­for/Ake­bia se­cure pri­or­i­ty re­view vouch­er

6 years ago

As­traZeneca sweeps two can­cer drugs to the scrap heap; Epizyme nabs pri­or­i­ty re­view for sec­ond rare can­cer NDA

6 years ago

Elan­co grabs $140M in deal with French phar­ma com­pa­ny; An­oth­er com­pa­ny an­nounces a coro­n­avirus vac­cine hunt

6 years ago
Coronavirus

Pre­vail's gene ther­a­py scores or­phan, rare pe­di­atric dis­ease priv­i­leges; Ger­many's ITM se­cures €40M loan

6 years ago

The Wuhan coro­n­avirus has an of­fi­cial name: COVID-19; Rev­o­lu­tion Med­i­cines up­sizes IPO terms

6 years ago
Coronavirus

Eye drop de­vel­op­er Oculis show­cas­es pos­i­tive PhII da­ta; Aque­s­tive hunts for an­oth­er FDA OK

6 years ago

Omega-backed start­up sells it­self qui­et­ly; Ab­b­Vie breaks out more Rin­voq da­ta; Re­vance gets FDA date for Botox ri­val

6 years ago

Drug pric­ing re­form ex­pect­ed to be biggest drag on bio­phar­ma in 2020; Beam up­sizes IPO of­fer­ing

6 years ago

Bay Area biotech CEO con­vict­ed of si­phon­ing off $2.6M to buy a home; Mer­ck wins Alzheimer's nod for in­som­nia pill

6 years ago

Rev­o­lu­tion Med­i­cines shoots for $150 mil­lion IPO; No­var­tis vet heads to Boston Phar­ma

6 years ago

Cure­Vac jumps in­to coro­n­avirus vac­cine race; EMA backs raft of drugs, in­clud­ing No­vo Nordisk, Es­pe­ri­on com­pounds

6 years ago
Coronavirus

The sec­ond, first AI de­vel­oped drug en­ters the clin­ic; Aprea gets break­through sta­tus for myelodys­plas­tic syn­dromes drug

6 years ago

Sanofi stops all but the most ur­gent trips to Chi­na; Flur­ry of or­phan drug des­ig­na­tions ar­rive

6 years ago

Sanofi/Re­gen­eron Dupix­ent; Alk­er­mes' an­tipsy­chot­ic get dates with the FDA; Con­cert wins re­prieve in In­cyte patent fight

6 years ago

PPD, Schrödinger, Beam set terms for IPO; FDA ex­pands use of Mer­ck­'s Di­fi­cid

6 years ago

Gilead dusts off a failed Ebo­la drug as coro­n­avirus spreads; Ex­elix­is boasts pos­i­tive Ph I/II da­ta

6 years ago
Coronavirus

British Heart Foun­da­tion un­veils short­list for £30M re­search award; On­cono­va scraps Chi­na part­ner­ship

6 years ago

Blue­print Med­i­cines po­ten­tial­ly de­lays Ay­vak­it de­ci­sion; Con­trol beats treat­ment in mesothe­lioma tri­al

6 years ago

As­traZeneca scores or­phan sta­tus for PD-L1/CT­LA-4 com­bo; EMA OKs No­var­tis' MS drug Mayzent

6 years ago

In­ter­cep­t's NASH de­ci­sion date is de­ferred; EMA in­ves­ti­gates safe­ty of LEO Phar­ma gel

6 years ago

Mayo Clin­ic launch­es clin­i­cal an­a­lyt­ics plat­form with nfer­ence; WuXi buys Ger­man plant from Bay­er

6 years ago

FDA grants pri­or­i­ty re­view for Rubra­ca; Arpeg­gio snags $3.2M in seed fi­nanc­ing

6 years ago

Ipsen re­cruits Steven Hilde­mann as CMO; Eli Lil­ly of­fers two more low-cost in­sulin op­tions

6 years ago

PACT Phar­ma bags $75M for neoanti­gen TCR work, man­u­fac­tur­ing; Bay­er grabs ex­per­i­men­tal con­tra­cep­tive from Daré

6 years ago
First page Previous page 42434445464748 Next page Last page
A service from the Financial Times